Laboratorios Farmaceuticos Rovi, S.A.

Total Valuation

Laboratorios Farmaceuticos Rovi, S.A. carries a market capitalization of 4.63B, placing it among publicly traded companies globally. Its enterprise value stands at 4.04B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Laboratorios Farmaceuticos Rovi, S.A. currently has 51.15M shares outstanding.

Valuation Ratios

Laboratorios Farmaceuticos Rovi, S.A. trades at a trailing price-to-earnings ratio of 30.43. The price-to-sales ratio is 5.41, and the price-to-book ratio stands at 6.77.

Enterprise Valuation

On an enterprise value basis, Laboratorios Farmaceuticos Rovi, S.A. trades at an EV/EBITDA multiple of 23.12 and an EV/FCF ratio of 16.13. The EV/Sales ratio of 5.45 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 23.12 provides insight into valuation relative to core operating earnings.

Financial Position

Laboratorios Farmaceuticos Rovi, S.A. maintains a current ratio of 3.66, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 16.66, indicating elevated leverage, while an interest coverage ratio of 64.33 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Laboratorios Farmaceuticos Rovi, S.A. posts a return on equity of 23.99 and a return on invested capital of 17.49.

Taxes

Over the trailing twelve months, Laboratorios Farmaceuticos Rovi, S.A. has paid 40.97M in income taxes, reflecting an effective tax rate of 23.72.

Stock Price Statistics

Laboratorios Farmaceuticos Rovi, S.A.'s stock has gained approximately 0% over the past 52 weeks. The 50-day moving average sits at 90.61, while the 200-day moving average is 90.61.

Income Statement

Over the trailing twelve months, Laboratorios Farmaceuticos Rovi, S.A. generated 741.09M in revenue and converted that into 131.82M in net income, yielding earnings per share of 2.58. EBITDA reached 174.78M, while operating income came in at 174.78M.

Balance Sheet

Laboratorios Farmaceuticos Rovi, S.A. holds 97.39M in cash and equivalents against 114.44M in total debt, resulting in a net debt position of -97.39M. Total book value stands at 592.39M, with working capital of 391.75M providing operational flexibility.

Cash Flow

Laboratorios Farmaceuticos Rovi, S.A. produced 181.19M in operating cash flow over the past twelve months. After subtracting -67.23M in capital expenditures, free cash flow totaled 113.96M - equivalent to 2.23 per share.

Margins

Laboratorios Farmaceuticos Rovi, S.A. operates with a gross margin of 65.47, reflecting its pricing power and cost economics. The operating margin of 23.58 and net profit margin of 17.79 provide insight into operational efficiency.

Dividends & Yields

Scores

Laboratorios Farmaceuticos Rovi, S.A. posts an Altman Z-Score of 12.98, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.